Effect of Total Amount of Metformin HCl on the Characteristics of Metformin-Ca Alginate Microspheres

Introduction: Metformin hydrochloride (metformin HCl) is an antidiabetic drug that is specifically used for type 2 diabetes mellitus (DM) and belongs to the biguanide antidiabetic drugs. Objective: The aim of this research was to determine the effect of total amount of metformin HCl on the characteristics of metformin HCl-Ca alginate microspheres using aerosolization technique. Methods: The total amount of metformin were 0.5 g (F1); 1 g (F2); 1.5 g (F3) and 2 g (F4). Drug was encapsulated into alginate and was crosslinked using CaCl2. Results: The results showed that drug loadings were 5.09%; 9.61%; 13.11%; and 15.09% respectively, while the entrapment efficiencies were 48.35%; 41.99%; 38.67%; and 30.53%. The yields were 80.92%; 74.12%; 68.27%; and 59.11% respectively. Based on the statistical analysis, it was found that there were significant differences between formulas. Particles of formulas decreased as the amount of drug increased. The resulting sizes were 1.82 μm (F1); 1.96 μm (F2); 2.1 μm (F3); and 2.97 μm (F4). Conclusion: It can be concluded that amount of drug significantly affected the characteristics of metformin-alginate microspheres.

Download Full-text

Insulin as Monotherapy and in Combination with Other Glucose-Lowering Drugs Is Related to Increased Risk of Diagnosis of Pneumonia: A Longitudinal Assessment over Two Years

Journal of Personalized Medicine ◽

10.3390/jpm11100984 ◽

2021 ◽

Vol 11 (10) ◽

pp. 984

Author(s):

Michael Leutner ◽

Michaela Kaleta ◽

Luise Bellach ◽

Alexander Kautzky ◽

Stefan Thurner ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Combination Therapy ◽

Drug Combinations ◽

Antidiabetic Drugs ◽

Control Group ◽

Antidiabetic Drug ◽

Increased Risk

Objective: Patients with type 2 diabetes mellitus (T2DM) are at an increased risk of developing infectious diseases such as pneumonia. Hitherto, there has been uncertainty as to whether there is a relationship between different antidiabetic drug combinations and development of pneumonia in this specific cohort. Research Design and Methods: In this longitudinal retrospective study we used multiple logistic regression analysis to assess the odds ratios (ORs) of pneumonia during an observational period of 2 years in 31,397 patients with T2DM under previously prescribed stable antidiabetic drug combinations over a duration of 4 years in comparison to 6568 T2DM patients without drug therapy over 4 years adjusted for age, sex and hospitalization duration. Results: Of the 37,965 patients with T2DM, 3720 patients underwent stable monotherapy treatment with insulin (mean age: 66.57 ± 9.72 years), 2939 individuals (mean age: 70.62 ± 8.95 y) received stable statin and insulin therapy, and 1596 patients were treated with a stable combination therapy of metformin, insulin and statins (mean age: 68.27 ± 8.86 y). In comparison to the control group without antidiabetic drugs (mean age: 72.83 ± 9.96 y), individuals undergoing insulin monotherapy (OR: 2.07, CI: 1.54–2.79, p < 0.001); insulin and statin combination therapy (OR: 2.24, CI: 1.68–3.00, p < 0.001); metformin, insulin and statin combination therapy (OR: 2.27, CI: 1.55–3.31, p < 0.001); statin, insulin and dipeptidyl peptidase-4 inhibitor (DPP-IV inhibitor) combination therapy (OR: 4.31, CI: 1.80–10.33, p = 0.001); as well as individuals treated with metformin and sulfonylureas (OR: 1.70, CI: 1.08–2.69, p = 0.02) were at increased risk of receiving a diagnosis of pneumonia. Conclusions: Stable monotherapy with insulin, but also in combination with other antidiabetic drugs, is related to an increased risk of being diagnosed with pneumonia during hospital stays in patients with type 2 diabetes mellitus compared to untreated controls.

Download Full-text

Abstract #292 Efficacy of Hydroxychloroquine when added in Subjects with Inadequately Controlled Type 2 Diabetes Mellitus Treated with Basal Insulin and Two Other Oral Antidiabetic Drugs

Endocrine Practice ◽

10.1016/s1530-891x(20)46636-4 ◽

2019 ◽

Vol 25 ◽

pp. 119-120

Author(s):

Arjun Baidya ◽

Ajay Chhabra

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Basal Insulin ◽

Antidiabetic Drugs ◽

Oral Antidiabetic Drugs ◽

Oral Antidiabetic

Download Full-text

Treatment patterns, persistence and adherence rates in patients with type 2 diabetes mellitus in Japan: a claims-based cohort study

BMJ Open ◽

10.1136/bmjopen-2018-025806 ◽

2019 ◽

Vol 9 (3) ◽

pp. e025806 ◽

Cited By ~ 21

Author(s):

Rimei Nishimura ◽

Haruka Kato ◽

Koichi Kisanuki ◽

Akinori Oh ◽

Shinzo Hiroi ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Drug Class ◽

Japanese Patients ◽

Medical Data ◽

Treatment Patterns ◽

Administrative Claims ◽

Antidiabetic Drug

ObjectiveTo determine real-world trends in antidiabetic drug use, and persistence and adherence, in Japanese patients with type 2 diabetes mellitus (T2DM).DesignRetrospective evaluation of administrative claims data (2011–2015) using the Japan Medical Data Center (JMDC) and Medical Data Vision (MDV) databases.SettingAnalysis of two administrative claims databases for Japanese patients with T2DM.ParticipantsAdults (aged ≥18 years) with an International Classification of Diseases, 10th Revision code of T2DM and at least one antidiabetic drug prescription.Main outcome measuresTreatment patterns in untreated (UT) or previously treated (PT) patients receiving antidiabetic therapy; persistence with treatment at 12 months; adherence to treatment at 12 months.Results40 908 and 90 421 patients were included from the JMDC and MDV databases, respectively. The most frequently prescribed therapy at the index (first prescription) date was dipeptidyl peptidase-4 inhibitor (DPP-4i) in UT patients (JMDC: 44.0%, MDV: 54.8%) and combination therapy in PT patients (74.6%, 81.1%). Most common combinations were DPP-4i plus: biguanide (BG; 11.4%, 10.9%), sulfonylurea (SU; 8.4%, 11.0%) or BG+SU (7.8%, 9.1%). In UT or PT patients from either database whose index prescription was for any antidiabetic drug class(es) other than DPP-4i, the most frequent add-on or switch was to DPP-4i. 12-month persistence with index monotherapy was highest with DPP-4i and BG. Adherence was high (≥80%) for all monotherapy schedules, except insulin and glucagon-like peptide-1 agonist, and for the five most frequent two-drug and three-drug combinations. Persistence was greater in elderly UT patients and in those receiving ≤5 medications, but comparatively worse in UT patients with ≥3 index antidiabetic drug classes.ConclusionsThe findings indicate that DPP-4i is the most commonly used antidiabetic drug class in Japanese patients with T2DM, and persistence and adherence to this antidiabetic drug class are high.

Download Full-text

Effect of sitagliptin on blood glucose control in patients with type 2 diabetes mellitus who are treatment naive or poorly responsive to existing antidiabetic drugs: the JAMP study

BMC Endocrine Disorders ◽

10.1186/s12902-016-0149-z ◽

2016 ◽

Vol 16 (1) ◽

Cited By ~ 8

Author(s):

Hiroshi Sakura ◽

◽

Naotake Hashimoto ◽

Kazuo Sasamoto ◽

Hiroshi Ohashi ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Blood Glucose ◽

Glucose Control ◽

Blood Glucose Control ◽

Antidiabetic Drugs ◽

Treatment Naïve

Download Full-text

Cost-effectiveness study of antidiabetic drugs in type 2 diabetes mellitus patients from Mumbai, India

International Journal of Community Medicine and Public Health ◽

10.18203/2394-6040.ijcmph20173653 ◽

2017 ◽

Vol 4 (9) ◽

pp. 3180 ◽

Cited By ~ 1

Author(s):

Dnyanesh Limaye ◽

Krishna Todi ◽

Jay Shroff ◽

Ashutosh Ramaswamy ◽

Priyanka Kulkarni ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Cost Effectiveness ◽

Cross Sectional Study ◽

Antidiabetic Drugs ◽

Cross Sectional ◽

Validated Questionnaire ◽

The Cost

Background: Diabetes is fast gaining the status of a potential epidemic in India, with >62 million individuals currently diagnosed with the disease. India currently faces an uncertain future in relation to the potential burden that diabetes may impose on the country. An estimated US$ 2.2 billion would be needed to sufficiently treat all cases of type 2 diabetes mellitus (T2DM) in India. Many interventions can reduce the burden of this disease. However, health care resources are limited; thus, interventions for diabetes treatment should be prioritized. The present study assesses the cost-effectiveness of antidiabetic drugs in patients with T2DM from Mumbai, India.Methods: A prospective cross-sectional study was performed to assess the cost-effectiveness of antidiabetic drugs in patients with T2DM. Face-to-face interviews were conducted by using a validated questionnaire in a total of 152 (76 males, 76 females) patients with T2DM from F-North Ward, Mumbai, India. Cost-effectiveness was determined on the basis of cost of antidiabetic drug/s, efficacy, adverse drug reactions, safety of administration, frequency of administration, and bioavailability. Results: For treatment of T2DM in non-obese participants, Glimepiride+Pioglitazone costed least (`3.7) per unit of effectiveness followed by Glimepiride (`6.6), Gliclazide (`8.1), Repaglinide (`24.5), and Vildagliptin (`45.2). For treatment of T2DM in obese participants, Metformin cost least (` 6.7) per unit of effectiveness followed by Glimepiride + Metformin (`5.9) and Repaglinide (`24.5). Conclusions: In case of non-obese participants, cost effectiveness and prescribed treatments did not show a match, while for obese participants prescribed treatments were in line with cost effectiveness.

Download Full-text